Amphista Therapeutics Funding: $61M Raised, Series B
Amphista Therapeutics is based in Cambridge, England. It has raised $61M in total funding. Latest round: Series B.
Amphista Therapeutics funding overview
Amphista Therapeutics is based in Cambridge, England. Amphista Therapeutics has raised $61M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B. Investors on record include Advent Life Sciences, Scottish Investment Bank, Scottish Growth Scheme, European Investment Fund, BioMotiv. 5 distinct backers are named across the disclosed rounds.
Amphista Therapeutics at a glance
Total raised
$61M
Latest round
Series B
Headquarters
Cambridge, England
Notable investors
Advent Life Sciences, Scottish Investment Bank, Scottish Growth Scheme, European Investment Fund, BioMotiv
Frequently asked about Amphista Therapeutics funding
How much has Amphista Therapeutics raised?
Amphista Therapeutics has raised $61M in total disclosed funding across the rounds on record.
Who has invested in Amphista Therapeutics?
Advent Life Sciences, Scottish Investment Bank, Scottish Growth Scheme, European Investment Fund, BioMotiv are named among the investors backing Amphista Therapeutics.
What was the latest Amphista Therapeutics funding round?
The most recent disclosed round is a Series B.
Where is Amphista Therapeutics based?
Amphista Therapeutics is based in Cambridge, England.
Amphista Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Cambridge below to benchmark round size and investor mix.
